Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
THLD's Cash to Debt is ranked higher than
97% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. THLD: No Debt )
THLD' s 10-Year Cash to Debt Range
Min: 18.21   Max: No Debt
Current: No Debt

Equity to Asset -0.23
THLD's Equity to Asset is ranked lower than
52% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. THLD: -0.23 )
THLD' s 10-Year Equity to Asset Range
Min: -0.23   Max: 0.88
Current: -0.23

-0.23
0.88
Interest Coverage No Debt
THLD's Interest Coverage is ranked higher than
74% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. THLD: No Debt )
THLD' s 10-Year Interest Coverage Range
Min: 725.64   Max: 9999.99
Current: No Debt

725.64
9999.99
F-Score: 3
Z-Score: -3.75
M-Score: 1.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -208.28
THLD's Operating margin (%) is ranked higher than
62% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. THLD: -208.28 )
THLD' s 10-Year Operating margin (%) Range
Min: -48445.16   Max: -208.28
Current: -208.28

-48445.16
-208.28
Net-margin (%) -227.41
THLD's Net-margin (%) is ranked higher than
62% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. THLD: -227.41 )
THLD' s 10-Year Net-margin (%) Range
Min: -41375.81   Max: -227.41
Current: -227.41

-41375.81
-227.41
ROA (%) -27.29
THLD's ROA (%) is ranked higher than
67% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. THLD: -27.29 )
THLD' s 10-Year ROA (%) Range
Min: -118.79   Max: -20.12
Current: -27.29

-118.79
-20.12
ROC (Joel Greenblatt) (%) -3793.59
THLD's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. THLD: -3793.59 )
THLD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8822.14   Max: 1436.47
Current: -3793.59

-8822.14
1436.47
EBITDA Growth (%) -15.70
THLD's EBITDA Growth (%) is ranked higher than
70% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. THLD: -15.70 )
THLD' s 10-Year EBITDA Growth (%) Range
Min: -73.4   Max: -15.7
Current: -15.7

-73.4
-15.7
EPS Growth (%) -4.40
THLD's EPS Growth (%) is ranked higher than
80% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. THLD: -4.40 )
THLD' s 10-Year EPS Growth (%) Range
Min: -85.5   Max: 2.7
Current: -4.4

-85.5
2.7
» THLD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

THLD Guru Trades in Q1 2013

Jean-Marie Eveillard 200,000 sh (unchged)
» More
Q2 2013

THLD Guru Trades in Q2 2013

Jean-Marie Eveillard 200,000 sh (unchged)
» More
Q3 2013

THLD Guru Trades in Q3 2013

Jim Simons 269,864 sh (New)
Steven Cohen 10,157 sh (New)
Jean-Marie Eveillard 200,000 sh (unchged)
» More
Q4 2013

THLD Guru Trades in Q4 2013

Steven Cohen 17,841 sh (+75.65%)
Jean-Marie Eveillard 200,000 sh (unchged)
Jim Simons 61,064 sh (-77.37%)
» More
» Details

Insider Trades

Latest Guru Trades with THLD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2012-12-31 New Buy$3.98 - $6.55 $ 3.83-18%200000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 18.24
THLD's P/S is ranked lower than
59% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. THLD: 18.24 )
THLD' s 10-Year P/S Range
Min: 1.77   Max: 1242
Current: 18.24

1.77
1242
PFCF 19.15
THLD's PFCF is ranked higher than
78% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 31.10 vs. THLD: 19.15 )
THLD' s 10-Year PFCF Range
Min: 5.29   Max: 38.3
Current: 19.15

5.29
38.3

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.04
THLD's Price/Median PS Value is ranked higher than
64% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. THLD: 1.04 )
THLD' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 38.03
Current: 1.04

0.18
38.03
Forward Rate of Return (Yacktman) -31.97
THLD's Forward Rate of Return (Yacktman) is ranked higher than
65% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. THLD: -31.97 )
THLD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 8.3   Max: 19.8
Current: -31.97

8.3
19.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NZW1.Germany
Threshold Pharmaceuticals, Inc. is a Delaware corporation incorporated in 2001. It's a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors as novel treatments for patients living with cancer. The microenvironment of these tissues is characterized by hypoxia or lack of oxygen. This hypoxic environment is known to be resistant to standard chemotherapy and radiation. It is thought to be responsible for the poor prognosis of patients with solid tumors and hematological malignancies and treating the hypoxic environment is currently believed to be a significant unmet medical need. Its hypoxia activated prodrug ("HAP") product candidates, including TH-302, are designed to specifically target the hypoxic microenvironment of tumors by selective activation of the prodrug to release a potent cytotoxin. Its focus is on product candidates for the treatment of patients with cancer. Its clinical development efforts are currently focused on TH-302, for which it entered a license and co-development agreement with Merck KGaA for worldwide development and commercialization. TH-302 is a novel drug candidate that is activated under severe hypoxic conditions and was designed to specifically target the severe hypoxic regions that are believed to be present in all solid tumors and hematologic malignancies. The production of TH-302 employs small molecule organic chemistry procedures that are standard for the pharmaceutical industry. It currently relies on contract manufacturers for the manufacture of active pharmaceutical ingredient ("API"), and final drug product of TH-302. Under its license and co-development agreement with Merck KGaA, the Company is dependent on Merck for clinical and commercial supply of TH-302, except for clinical trials for United States approval of TH-302 for soft tissue sarcoma and for any other clinical trials for which it is responsible. For these latter cases, it can obtain clinical supply directly from existing or new suppliers. It currently uses contract manufacturers to manufacture TH-302 API and TH-302 drug product. Its competitors are AstraZeneca PLC, Genentech, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Bayer Pharmaceuticals, Hoffmann-LaRoche, Inc., Johnson & Johnson, Onyx Pharmaceuticals, Inc., Merck KGaA, Novartis AG, Pfizer, Inc., Amgen Inc., ImClone Systems, Inc., Millennium Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc., Telik, Inc., Sunesis Pharmaceuticals, Inc., Plexxikon Inc., Celgene Corporation, Abraxis Bioscience Inc., ARIAD Pharmaceuticals, Inc. and ZIOPHARM Oncology, Inc. The manufacturing and marketing of its potential products and its ongoing research and development activities are subject to extensive regulation by the FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide